製剤開発アウトソーシング市場は、製剤の複雑さの増大に加え、革新的な医薬品に対する高い需要と、製薬会社やバイオテクノロジー企業による手頃な戦略の採用により、予測期間中に715億ドルに達すると予測されます。企業が製剤方法を改善するために外部の専門知識を求めているため、アウトソーシング協力が大幅に増加しています。さらに、グローバルな状況は、専門的な製剤サービスを提供する医薬品開発業務受託機関(CRO)や医薬品開発製造受託機関(CDMO)が豊富に存在することによって定義されています。さらに、厳しい規制ニーズと製薬技術の急速な改善が、製剤開発アウトソーシング市場の成長に寄与しています。その結果、業界が研究開発活動に継続的に注力しているため、市場は着実に上昇すると予想されます。
目次
Table of Content
1. Executive Summary
1.1. Regional Market Share
1.2. Business Trends
1.3. Formulation Development Outsourcing Market: COVID-19 Outbreak
1.4. Regional Trends
1.5. Segmentation Snapshot
2. Research Methodology
2.1. Research Objective
2.2. Research Approach
2.3. Data Sourcing and Methodology
2.4. Primary Research
2.5. Secondary Research
2.5.1. Paid Sources
2.5.2. Public Sources
2.6. Market Size Estimation and Data Triangulation
3. Market Characteristics
3.1. Market Definition
3.2. Formulation Development Outsourcing Market: COVID-19 Impact
3.3. Key Segmentations
3.4. Key Developments
3.5. Allied Industry Data
4. Formulation Development Outsourcing Market - Industry Insights
4.1. Industry Segmentation
4.2. COVID-19 overview on world economy
4.3. Industry ecosystem Channel analysis
4.4. Innovation & Sustainability
5. Macroeconomic Indicators
6. Recent Developments
7. Market Dynamics
7.1. Introduction
7.2. Growth Drivers
7.3. Market Opportunities
7.4. Market Restraints
7.5. Market Trends
8. Risk Analysis
9. Market Analysis
9.1. Porters Five Forces
9.2. PEST Analysis
9.2.1. Political
9.2.2. Economic
9.2.3. Social
9.2.4. Technological
10. Formulation Development Outsourcing Market
10.1. Overview
10.2. Historical Analysis (2019-2022)
10.2.1. Market Size, Y-o-Y Growth (%) and Market Forecast
11. Formulation Development Outsourcing Market Size & Forecast 2024A-2034F
11.1. Overview
11.2. Key Findings
11.3. Market Segmentation
11.3.1. By Service
11.3.1.1. Pre-Formulation
11.3.1.1.1. By Value (USD Million) 2024-2034F
11.3.1.1.2. Market Share (%) 2024-2034F
11.3.1.1.3. Y-o-Y Growth (%) 2024-2034F
11.3.1.2. Formulation Development
11.3.1.2.1. By Value (USD Million) 2024-2034F
11.3.1.2.2. Market Share (%) 2024-2034F
11.3.1.2.3. Y-o-Y Growth (%) 2024-2034F
11.3.2. By Formulation
11.3.2.1. Oral
11.3.2.1.1. By Value (USD Million) 2024-2034F
11.3.2.1.2. Market Share (%) 2024-2034F
11.3.2.1.3. Y-o-Y Growth (%) 2024-2034F
11.3.2.2. Injectable
11.3.2.2.1. By Value (USD Million) 2024-2034F
11.3.2.2.2. Market Share (%) 2024-2034F
11.3.2.2.3. Y-o-Y Growth (%) 2024-2034F
11.3.2.3. Topical
11.3.2.3.1. By Value (USD Million) 2024-2034F
11.3.2.3.2. Market Share (%) 2024-2034F
11.3.2.3.3. Y-o-Y Growth (%) 2024-2034F
11.3.2.4. Inhaled
11.3.2.4.1. By Value (USD Million) 2024-2034F
11.3.2.4.2. Market Share (%) 2024-2034F
11.3.2.4.3. Y-o-Y Growth (%) 2024-2034F
11.3.3. By Application
11.3.3.1. Oncology
11.3.3.1.1. By Value (USD Million) 2024-2034F
11.3.3.1.2. Market Share (%) 2024-2034F
11.3.3.1.3. Y-o-Y Growth (%) 2024-2034F
11.3.3.2. Infectious Diseases
11.3.3.2.1. By Value (USD Million) 2024-2034F
11.3.3.2.2. Market Share (%) 2024-2034F
11.3.3.2.3. Y-o-Y Growth (%) 2024-2034F
11.3.3.3. Neurology
11.3.3.3.1. By Value (USD Million) 2024-2034F
11.3.3.3.2. Market Share (%) 2024-2034F
11.3.3.3.3. Y-o-Y Growth (%) 2024-2034F
11.3.3.4. Hematology
11.3.3.4.1. By Value (USD Million) 2024-2034F
11.3.3.4.2. Market Share (%) 2024-2034F
11.3.3.4.3. Y-o-Y Growth (%) 2024-2034F
11.3.3.5. Respiratory
11.3.3.5.1. By Value (USD Million) 2024-2034F
11.3.3.5.2. Market Share (%) 2024-2034F
11.3.3.5.3. Y-o-Y Growth (%) 2024-2034F
11.3.3.6. Cardiovascular
11.3.3.6.1. By Value (USD Million) 2024-2034F
11.3.3.6.2. Market Share (%) 2024-2034F
11.3.3.6.3. Y-o-Y Growth (%) 2024-2034F
11.3.3.7. Dermatology
11.3.3.7.1. By Value (USD Million) 2024-2034F
11.3.3.7.2. Market Share (%) 2024-2034F
11.3.3.7.3. Y-o-Y Growth (%) 2024-2034F
11.3.4. By End-User
11.3.4.1. Pharmaceutical Industries
11.3.4.1.1. By Value (USD Million) 2024-2034F
11.3.4.1.2. Market Share (%) 2024-2034F
11.3.4.1.3. Y-o-Y Growth (%) 2024-2034F
11.3.4.2. Research and Academic Institutes
11.3.4.2.1. By Value (USD Million) 2024-2034F
11.3.4.2.2. Market Share (%) 2024-2034F
11.3.4.2.3. Y-o-Y Growth (%) 2024-2034F
11.3.4.3. Others
11.3.4.3.1. By Value (USD Million) 2024-2034F
11.3.4.3.2. Market Share (%) 2024-2034F
11.3.4.3.3. Y-o-Y Growth (%) 2024-2034F
12. North America Formulation Development Outsourcing Market Size & Forecast 2024A-2034F
12.1. Overview
12.2. Key Findings
12.3. Market Segmentation
12.3.1. By Service
12.3.2. By Formulation
12.3.3. By Application
12.3.4. By End-User
12.4. Country
12.4.1. United States
12.4.2. Canada
13. Europe Formulation Development Outsourcing Market Size & Forecast 2024A-2034F
13.1. Overview
13.2. Key Findings
13.3. Market Segmentation
13.3.1. By Service
13.3.2. By Formulation
13.3.3. By Application
13.3.4. By End-User
13.4. Country
13.4.1. Germany
13.4.2. United Kingdom
13.4.3. France
13.4.4. Italy
13.4.5. Spain
13.4.6. Russia
13.4.7. Rest of Europe (BENELUX, NORDIC, Hungary, Turkey & Poland)
14. Asia-Pacific Formulation Development Outsourcing Market Size & Forecast 2024A-2034F
14.1. Overview
14.2. Key Findings
14.3. Market Segmentation
14.3.1. By Service
14.3.2. By Formulation
14.3.3. By Application
14.3.4. By End-User
14.4. Country
14.4.1. India
14.4.2. China
14.4.3. South Korea
14.4.4. Japan
14.4.5. Rest of APAC
15. Middle East and Africa Formulation Development Outsourcing Market Size & Forecast 2024A-2034F
15.1. Overview
15.2. Key Findings
15.3. Market Segmentation
15.3.1. By Service
15.3.2. By Formulation
15.3.3. By Application
15.3.4. By End-User
15.4. Country
15.4.1. Israel
15.4.2. GCC
15.4.3. North Africa
15.4.4. South Africa
15.4.5. Rest of Middle East and Africa
16. Latin America Formulation Development Outsourcing Market Size & Forecast 2024A-2034F
16.1. Overview
16.2. Key Findings
16.3. Market Segmentation
16.3.1. By Service
16.3.2. By Formulation
16.3.3. By Application
16.3.4. By End-User
16.4. Country
16.4.1. Mexico
16.4.2. Brazil
16.4.3. Rest of Latin America
17. Competitive Landscape
17.1. Company market share, 2023
17.2. Key player overview
17.3. Key stakeholders
18. Company Profiles
18.1. Catalent, Inc.
18.1.1. Company Overview
18.1.2. Financial Overview
18.1.3. Key Product; Analysis
18.1.4. Company Assessment
18.1.4.1. Product Portfolio
18.1.4.2. Key Clients
18.1.4.3. Market Share
18.1.4.4. Recent News & Development (Last 3 Yrs.)
18.1.4.5. Executive Team
18.2. Lonza Group
18.3. Recipharm AB
18.4. Evonik Industries AG
18.5. Jubilant Life Sciences
18.6. Patheon
18.7. Cambrex Corporation
18.8. Aptuit
18.9. Metrics Contract Services
18.10. AMRI (Albany Molecular Research Inc.)
18.11. Curia
18.12. Charles River Laboratories
18.13. WuXi AppTec
18.14. PPD, Inc.
18.15. Pharmaceutics International, Inc.
18.16. Other Prominent Players
19. Appendix
20. Consultant Recommendation
